Clinical trial

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC

NCT05904015

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2023-08-01

PhasePHASE2

Study timeline

Study start (estimated)2023-08-01Date precision: day

Registry last updated2023-06-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Neoplasmsunresolved

Interventions

Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)DRUG

Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)DRUG

Sponsors & collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Scienceslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05904015 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.